Fate Therapeutics Ownership
| FATE Stock | USD 2.07 0.15 6.76% |
Shares in Circulation | First Issued 2012-09-30 | Previous Quarter 117.5 M | Current Value 117.8 M | Avarage Shares Outstanding 58.9 M | Quarterly Volatility 34 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Fate |
Fate Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fate Therapeutics recorded a loss per share of 1.64. The entity had not issued any dividends in recent years. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. Fate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 542 people. To learn more about Fate Therapeutics call Scott Wolchko at 858 875 1800 or check out https://www.fatetherapeutics.com.Besides selling stocks to institutional investors, Fate Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Fate Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Fate Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Fate Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Fate Therapeutics Insider Trades History
Roughly 2.0% of Fate Therapeutics are currently held by insiders. Unlike Fate Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Fate Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Fate Therapeutics' insider trades
Fate Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fate Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fate Therapeutics backward and forwards among themselves. Fate Therapeutics' institutional investor refers to the entity that pools money to purchase Fate Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Johnson & Johnson | 2024-06-30 | 3.4 M | Baker Bros Advisors Lp | 2024-09-30 | 3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.6 M | Assenagon Asset Management Sa | 2024-09-30 | 2.4 M | Goldman Sachs Group Inc | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-06-30 | 2.2 M | Vestal Point Capital Lp | 2024-06-30 | 2 M | Bank Of America Corp | 2024-06-30 | 2 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1.7 M | Redmile Group, Llc | 2024-09-30 | 13.2 M | Vanguard Group Inc | 2024-09-30 | 10.4 M |
Fate Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fate Therapeutics Outstanding Bonds
Fate Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fate Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fate bonds can be classified according to their maturity, which is the date when Fate Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Fate Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 21st of August 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 7th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.123 | Quarterly Revenue Growth 0.581 | Return On Assets (0.22) | Return On Equity (0.47) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.